ATE255903T1 - Stabilisierende formulierung für ngf - Google Patents

Stabilisierende formulierung für ngf

Info

Publication number
ATE255903T1
ATE255903T1 AT96937710T AT96937710T ATE255903T1 AT E255903 T1 ATE255903 T1 AT E255903T1 AT 96937710 T AT96937710 T AT 96937710T AT 96937710 T AT96937710 T AT 96937710T AT E255903 T1 ATE255903 T1 AT E255903T1
Authority
AT
Austria
Prior art keywords
ngf
stabilizing formulation
stabilizing
formulation
maturation
Prior art date
Application number
AT96937710T
Other languages
English (en)
Inventor
Young Linda R De
Xanthe M Lam
Tue Nguyen
Michael F Powell
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24214304&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE255903(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE255903T1 publication Critical patent/ATE255903T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
AT96937710T 1995-11-07 1996-10-21 Stabilisierende formulierung für ngf ATE255903T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55468595A 1995-11-07 1995-11-07
PCT/US1996/016881 WO1997017087A1 (en) 1995-11-07 1996-10-21 Stabilizing formulation for ngf

Publications (1)

Publication Number Publication Date
ATE255903T1 true ATE255903T1 (de) 2003-12-15

Family

ID=24214304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937710T ATE255903T1 (de) 1995-11-07 1996-10-21 Stabilisierende formulierung für ngf

Country Status (18)

Country Link
EP (1) EP0862452B1 (de)
JP (1) JP4057058B2 (de)
KR (1) KR100497087B1 (de)
CN (1) CN1126567C (de)
AT (1) ATE255903T1 (de)
AU (1) AU721112B2 (de)
BR (1) BR9611571B1 (de)
CA (1) CA2234231C (de)
DE (1) DE69631063T2 (de)
DK (1) DK0862452T3 (de)
ES (1) ES2211991T3 (de)
HK (1) HK1015261A1 (de)
IL (1) IL124004A (de)
MX (1) MX9803342A (de)
PT (1) PT862452E (de)
TR (1) TR199800811T2 (de)
WO (1) WO1997017087A1 (de)
ZA (1) ZA969290B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7214998A (en) * 1997-04-11 1998-11-11 Regents Of The University Of California, The Ngf for the prevention of demyelination in the nervous system
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
JP4719357B2 (ja) † 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
EP1407770B1 (de) * 2001-06-26 2013-06-05 Takeda Pharmaceutical Company Limited Tgf-beta superfamilien-produktion/sekretions-promoter
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
EA012565B1 (ru) 2003-04-02 2009-10-30 Арес Трейдинг С.А. Жидкие фармацевтические композиции фолликулостимулирующего гормона (фсг) и лютеинизирующего гормона (лг), содержащие неионогенное поверхностно-активное вещество
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
CA2526099C (en) 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
CN108348579B (zh) * 2015-04-21 2021-04-27 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物及注射粉剂
US10405504B2 (en) * 2016-01-04 2019-09-10 Grape King Bio Ltd. Active substances for preventing hearing deterioration, the composition containing the active substances, and the preparation method thereof
CN114252519B (zh) * 2020-09-23 2023-11-24 舒泰神（北京）生物制药股份有限公司 一种测定神经生长因子纯度的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor

Also Published As

Publication number Publication date
BR9611571A (pt) 1999-03-30
CN1201394A (zh) 1998-12-09
CA2234231C (en) 2009-04-14
EP0862452B1 (de) 2003-12-10
AU721112B2 (en) 2000-06-22
BR9611571B1 (pt) 2009-01-13
JP4057058B2 (ja) 2008-03-05
MX9803342A (es) 1998-09-30
TR199800811T2 (xx) 1998-07-21
WO1997017087A1 (en) 1997-05-15
DK0862452T3 (da) 2004-04-05
DE69631063T2 (de) 2004-09-30
IL124004A (en) 2003-10-31
CN1126567C (zh) 2003-11-05
PT862452E (pt) 2004-04-30
ZA969290B (en) 1998-05-05
KR100497087B1 (ko) 2005-09-09
CA2234231A1 (en) 1997-05-15
JP2002502358A (ja) 2002-01-22
KR19990067350A (ko) 1999-08-16
HK1015261A1 (en) 1999-10-15
DE69631063D1 (de) 2004-01-22
EP0862452A1 (de) 1998-09-09
ES2211991T3 (es) 2004-07-16
AU7518696A (en) 1997-05-29

Similar Documents

Publication Publication Date Title
ATE255903T1 (de) Stabilisierende formulierung für ngf
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
DE69024965D1 (de) Dehydrodidemnin b
MX9206008A (es) Inhibidores de enzima proteolitica, derivados de sacarina 2-substituida.
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
BR9407278A (pt) Formulações farmacêuticas do fator de crescimento dos nervos
DK0608912T3 (da) Synergistiske mikrobicide sammensætninger
ATE237633T1 (de) Analogen des keratinozytenwachstumfaktors
YU72194A (sh) Injekcione suspenzije sa produženim dejstvom i postupak za proizvodnju istih
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
GB9616896D0 (en) Pharmaceutical compositions
ATE174383T1 (de) Verwendung von tri-n-butylphosphat bei niedrigem ph in lösungen von biologisch aktiven proteinen für eine verbesserte viruzide wirkung
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
DE69425061D1 (de) Verwendung von einer suspension auf der basis von sucralfatgel als antazidum
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.
ES2186782T3 (es) Uso de derivados de tropolona como inhibidores de la enzima inositol-monofosfatasa.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0862452

Country of ref document: EP